ABEO Abeona Therapeutics Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: ABEO

Price (delayed)

$7.53

Market cap

$205.98M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.53

Enterprise value

$196.57M

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing gene and cell therapies for serious diseases. Abeona's clinical programs include EB-101, its autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis ...

Highlights
The company's gross profit has surged by 148% YoY
The revenue has soared by 148% year-on-year
ABEO's EPS has dropped by 78% since the previous quarter but it has soared by 54% year-on-year
Abeona Therapeutics's equity has decreased by 45% YoY and by 33% QoQ
The company's quick ratio fell by 39% YoY and by 39% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://abeonatherapeutics.com
Peers: MRK TXMD

Key stats

What are the main financial stats of ABEO
Market
Shares outstanding
27.36M
Market cap
$205.98M
Enterprise value
$196.57M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
12.58
Price to sales (P/S)
46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
56.16
Earnings
Revenue
$3.5M
EBIT
-$53.77M
EBITDA
-$50.57M
Free cash flow
-$37.14M
Per share
EPS
-$2.53
Free cash flow per share
-$1.74
Book value per share
$0.6
Revenue per share
$0.16
TBVPS
$2.99
Balance sheet
Total assets
$64M
Total liabilities
$49.18M
Debt
$5.4M
Equity
$14.83M
Working capital
$42.32M
Liquidity
Debt to equity
0.36
Current ratio
4.15
Quick ratio
4.1
Net debt/EBITDA
0.19
Margins
EBITDA margin
-1,444.9%
Gross margin
100%
Net margin
-1,548.2%
Operating margin
-1,300.9%
Efficiency
Return on assets
-91.5%
Return on equity
-333.7%
Return on invested capital
-112.5%
Return on capital employed
-106.3%
Return on sales
-1,536.3%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

ABEO stock price

How has the Abeona Therapeutics stock price performed over time
Intraday
0%
1 week
-0.26%
1 month
-0.53%
1 year
139.05%
YTD
50.3%
QTD
3.86%

Financial performance

How have Abeona Therapeutics's revenue and profit performed over time
Revenue
$3.5M
Gross profit
$3.5M
Operating income
-$45.53M
Net income
-$54.19M
Gross margin
100%
Net margin
-1,548.2%
The company's gross profit has surged by 148% YoY
The revenue has soared by 148% year-on-year
ABEO's operating margin has soared by 64% YoY but it is down by 2.8% QoQ
Abeona Therapeutics's net margin has increased by 45% YoY but it has decreased by 24% QoQ

Growth

What is Abeona Therapeutics's growth rate over time

Valuation

What is Abeona Therapeutics stock price valuation
P/E
N/A
P/B
12.58
P/S
46
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
56.16
ABEO's EPS has dropped by 78% since the previous quarter but it has soared by 54% year-on-year
The price to book (P/B) is 110% higher than the last 4 quarters average of 6.0
Abeona Therapeutics's equity has decreased by 45% YoY and by 33% QoQ
The revenue has soared by 148% year-on-year
ABEO's P/S is 47% above its last 4 quarters average of 31.2 and 19% above its 5-year quarterly average of 38.5

Efficiency

How efficient is Abeona Therapeutics business performance
Abeona Therapeutics's return on equity has shrunk by 80% YoY and by 43% QoQ
ABEO's ROS is up by 44% year-on-year but it is down by 24% since the previous quarter
The company's return on invested capital fell by 27% QoQ but it rose by 9% YoY
The company's return on assets fell by 21% QoQ and by 7% YoY

Dividends

What is ABEO's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ABEO.

Financial health

How did Abeona Therapeutics financials performed over time
The company's total assets is 30% higher than its total liabilities
The company's quick ratio fell by 39% YoY and by 39% QoQ
The current ratio has declined by 39% year-on-year and by 39% since the previous quarter
Abeona Therapeutics's debt is 64% lower than its equity
Abeona Therapeutics's equity has decreased by 45% YoY and by 33% QoQ
Abeona Therapeutics's debt to equity has increased by 38% QoQ and by 24% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.